02:02 PM EDT, 04/03/2025 (MT Newswires) -- Health care stocks were lower Thursday afternoon, with the NYSE Health Care Index down 0.2% and the Health Care Select Sector SPDR Fund (XLV) shedding 0.3%.

The iShares Biotechnology ETF (IBB) fell 1.9%.

In sector news, pharmaceuticals appear to have dodged reciprocal tariffs imposed by President Donald Trump, but it may be premature to celebrate, analysts at RBC Capital Markets said.

In corporate news, Sarepta Therapeutics ( SRPT ) shares fell more than 5% after media reports that the European Medicines Agency has placed a temporary hold on enrollment and dosing in multiple ongoing trials of the company's gene therapy Elevidys for Duchenne muscular dystrophy.

RxSight ( RXST ) shares dropped past 38% after it lowered its 2025 revenue guidance range to between $160 million and $175 million from its previous projection of $185 million to $197 million.

Edgewise Therapeutics' ( EWTX ) management strongly believes that atrial fibrillation reported by some patients in a phase 2 study was not driven by EDG-7500 as there is no correlation between the cases and higher exposure to the drug, RBC Capital Markets said in a note on Wednesday. Edgewise shares fell 13%.